ALG-1007 is under clinical development by Allegro Ophthalmics and currently in Phase II for Keratoconjunctivitis Sicca (Dry Eye). According to GlobalData, Phase II drugs for Keratoconjunctivitis Sicca (Dry Eye) have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ALG-1007’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ALG-1007 overview

ALG-1007 is under development for the treatment of dry eye disease. The therapeutic candidate is formulated as drops-solution and is administered through ophthalmic route. It acts by targeting integrin alpha V and Beta 1,2 and 3.

Allegro Ophthalmics overview

Allegro Ophthalmics is an ophthalmic pharmaceutical company. The company uses integrin-regulating therapy for the treatment of vascular eye diseases. Allegro Ophthalmics is headquartered in San Juan Capistrano, California, the US.

For a complete picture of ALG-1007’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.